Trial Profile
A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- 31 Jan 2024 Planned End Date changed from 19 Jan 2024 to 30 Jan 2025.
- 02 Feb 2023 Planned End Date changed from 19 Jan 2023 to 19 Jan 2024.
- 31 May 2020 Results establishing if BMB add value in assessing response or identify distinct progression free (PFS) or overall survival (OS) outcomes in a large, multicenter, multi-trial cohort presented at the 56th Annual Meeting of the American Society of Clinical Oncology